Breaking News Instant updates and real-time market news.

ACRX

AcelRx

$3.81

0.1 (2.70%)

04:55
10/11/16
10/11
04:55
10/11/16
04:55

AcelRx management to meet with Roth Capital

Meetings to be held in Baltimore on October 10 and in Boston on October 11 hosted by Roth Capital.

  • 11

    Oct

ACRX AcelRx
$3.81

0.1 (2.70%)

04/14/16
JANY
04/14/16
INITIATION
Target $11
JANY
Neutral
AcelRx initiated with a Neutral at Janney Capital
Target $11.
04/14/16
04/14/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Symantec (SYMC) initiated with a Sell at Evercore ISI by analyst Ken Talanian, who found it unclear whether the current management will be able to "facilitate significant change." He adds that the stock's current valuation overestimates the company's ability to reduce cost and return to growth. 2. Insys Therapeutics (INSY) initiated with a Buy at Janney Capital with analyst Ken Trbovich saying the company's pipeline is "too compelling to ignore." He said that the FDA approval and launch of its Syndros product should offset the weakness from Subsys. 3. Simon Property (SPG) initiated with a Buy at Mizuho. 4. AcelRx (ACRX) initiated with a Neutral at Janney Capital. 5. Intuit (INTU) initiated with a Buy at Brean Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/15/16
ROTH
09/15/16
NO CHANGE
Target $15
ROTH
Buy
AcelRx price target raised to $15 from $11 at Roth Capital
10/04/16
JEFF
10/04/16
NO CHANGE
Target $7
JEFF
Buy
Jefferies says physician survey bodes well for AcelRx
Jefferies analyst Hugo Ong says his firm's first Emergency Department physician survey on trends for acute pain management suggests a positive outlook for AcelRx's ARX-04. Physicians expect to use the drug, which could be available by the end of 2017, in 19% of their patients with moderate pain and 27% with severe pain in 2018, Ong tells investors in a research note. He believes the survey bodes well for ARX-04 and reiterates a Buy rating on AcelRx with a $7 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.